A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: Nucleotide excision repair (NER) as potential chemoresistance marker

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 3, 2013, Pages 789-797

  Hirakawa, Masahiro ^a   Sato, Yasushi ^a   Ohnuma, Hiroyuki ^a   Takayama, Tetsuji ^b   Sagawa, Tamotsu ^c   Nobuoka, Takayuki ^a   Harada, Keisuke ^a   Miyamoto, Hiroshi ^b   Sato, Yasuhiro ^c   Takahashi, Yasuo ^c   Katsuki, Shinich ^d   Hirayama, Michiaki ^e   Takahashi, Minoru ^f   Ono, Michihiro ^g   Maeda, Masahiro ^g   Takada, Kohichi ^a   Hayashi, Tsuyoshi ^a   Sato, Tsutomu ^a   Miyanishi, Koji ^a   Takimoto, Rishu ^a   Kobune, Masayoshi ^a   Hirata, Koichi ^a   Kato, Junji ^a   more..

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d Otaru Ekisaikai Hospital   (Japan)

^e Tonan Hospital   (Japan)

^f Division of Gastroenterology   (Japan)

^g Steel Memorial Muroran Hospital   (Japan)

Author keywords

Advanced resectable gastric cancer; DSC; Neoadjuvant chemotherapy; Nucleotide excision repair

Indexed keywords

CISPLATIN; DNA BINDING PROTEIN; DNA BINDING PROTEIN COMPLEX SUBUNIT 2; DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; TUMOR MARKER; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BIOLOGICAL MARKER; DDB2 PROTEIN, HUMAN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; OTERACIL; S 1 (COMBINATION); TAXOID; TEGAFUR;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EXCISION REPAIR; FATIGUE; FEMALE; GASTROJEJUNOSTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LYMPH NODE METASTASIS; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIDE EFFECT; STOMACH BIOPSY; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADJUVANT THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DNA REPAIR; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; ENDOSCOPIC ECHOGRAPHY; FOLLOW UP; GENETICS; KAPLAN MEIER METHOD; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CISPLATIN; COMBINED MODALITY THERAPY; DNA REPAIR; DNA-BINDING PROTEINS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; ENDOSONOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OXONIC ACID; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TEGAFUR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84875843655     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2073-5     Document Type: Article

References (30)

1. Jemal A, Center MM, DeSantis C et al (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907
2. Shi Y, Zhou Y (2010) The role of surgery in the treatment of gastric cancer. J Surg Oncol 101:687-692
3. Songun I, Putter H, Kranenbarg EM et al (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439-449
4. Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820 (Pubitemid 350044801)
5. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
6. Ychou M, Boige V, Pignon JP et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715-1721
7. Ajani JA (2005) Evolving chemotherapy for advanced gastric cancer. Oncologist 10:49-58 (Pubitemid 43153809)
8. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24:4991-4997 (Pubitemid 46631401)
9. Ajani JA, Rodriguez W, Bodoky G et al (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28:1547-1553
10. Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221
11. Takayama T, Sato Y, Sagawa T et al (2007) Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Br J Cancer 97:851-856 (Pubitemid 47519303)
12. Sato Y, Takayama T, Sagawa T et al (2010) Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 66:721-728
13. Koizumi W, Nakayama N, Tanabe S et al (2012) A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol 69(2):407-413
14. Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma - 2nd english edition. Gastric Cancer 1:10-24
15. Japanese Gastric Cancer Association (2001) Japanese classification of gastric carcinoma - 2nd english edition - response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer 4:1-8 (Pubitemid 32625928)
16. Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd english edition. Gastric Cancer 14:101-112
17. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ (2007) Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18(3):504-509 (Pubitemid 46359630)
18. Schuhmacher CP, Fink U, Becker K et al (2001) Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 91:918-927
19. Yoshikawa T, Sasako M, Yamamoto S et al (2009) Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 96:1015-1022
20. Kinoshita T, Sasako M, Sano T et al (2009) Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer 12:37-42
21. Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN, Parsons SL, Madhusudan S (2010) Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 102(11):1600-1607
22. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K (2008) Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 98(4):832-839 (Pubitemid 351272605)
23. Takimoto R, MacLachlan TK, Dicker DT, Niitsu Y, Mori T, el-Deiry WS (2002) BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol Ther 1(2):177-186
24. Li W, Qin J, Sun YH et al (2010) Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol 16:5621-5628
25. De Vita F, Giuliani F, Galizia G et al (2007) Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 18(Suppl 6):120-123
26. Mezhir JJ, Tang LH, Coit DG (2010) Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol 101:305-314
27. Saka M, Morita S, Fukagawa T et al (2011) Present and future status of gastric cancer surgery. Jpn J Clin Oncol 41:307-313
28. Kawashima Y, Sasako M, Tsuburaya A et al (2008) Phase II study of preoperative neoadjuvant chemotherapy (CX) with S-1 plus cisplatin for gastric cancer (GC) with bulky and/or para-aortic lymph node metastases: a Japan clinical oncology group study (JCOG0405). In: ASCO gastrointestinal cancers symposium. Abstract no. 118, San Francisco
29. Fujitani K, Sasako M, Iwasaki Y et al (2007) A phase II study of preoperative chemotherapy (CX) with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancer. JCOG 0210 J Clin Oncol 25:18 (suppl; abstr 4609)
30. Ajani JA, Mansfield PF, Crane CH et al (2005) Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23:1237-1244 (Pubitemid 46202281)